High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: CX3CL1 is the only CX3C chemokine that can chemoattract T cells, natural killer (NK) cells, and dendritic cells (DCs). The role of CX3CL1 in breast carcinoma remains unknown. Methods: Immunohistochemical staining for CX3CL1, CD8, CD57, and CD1a was performed on 204 breast carcinoma specimens using tissue microarray blocks to determine whether CX3CL1 expression correlated with a good prognosis and antitumor immunity. Results: The number of stromal CD8+ T cells, intratumoral CD1a+ DCs, and stromal CD57+ NK cells were significantly increased in the high CX3CL1 expression group compared with those in the low CX3CL1expression group. Patients with high CX3CL1 expression had a significantly better disease‐free and overall survival than those with low CX3CL1 expression (P = 0.002 and P < 0.001, respectively). CX3CL1 expression was identified as one of the independent prognostic factors for disease‐free and overall survival (P = 0.046 and P = 0.010, respectively). Conclusion: The expression of CX3CL1 by tumor cells appears to enhance the recruitment of CD8+ T cells, CD57+ NK cells, and CD1a+ DCs, thereby bringing about a better prognosis in breast carcinoma. CX3CL1 is a new prognostic biomarker and may be a novel candidate for development of a more effective therapeutic strategy for breast carcinoma. J. Surg. Oncol. 2012; 106:386–392. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Research works printed but not linked: 28
- 10.3346/jkms.2010.25.8.1113 · DOI · Paper page
- 10.3816/CBC.2003.s.018 · doi:10.3816/cbc.2003.s.018
- 10.1089/gtmb.2009.0060 · DOI
- 10.1517/14656566.9.15.2639 · DOI
- Wei S, 2005, Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells, Discov Med, 5, 489
- 10.1038/sj.bjc.6690780 · doi:10.1038/sj.bjc.6690780
- 10.1038/nrc928 · DOI · Paper page
- 10.1016/S0140-6736(05)17717-4 · DOI
- 10.1016/j.imlet.2004.05.006 · DOI
- 10.1016/S1074-7613(00)80165-X · DOI · Paper page
- 10.1016/S0076-6879(09)05201-X · DOI
- 10.1016/S0092-8674(00)80438-9 · DOI · Paper page
- 10.1002/ijc.10816 · DOI · Paper page
- Lavergne E, 2003, Fractalkine mediates natural killer‐dependent antitumor responses in vivo, Cancer Res, 63, 7468
- 10.1002/eji.200526042 · DOI · Paper page
- 10.1002/eji.200535549 · DOI · Paper page
- Ohta M, 2005, The high expression of Fractalkine results in a better prognosis for colorectal cancer patients, Int J Oncol, 26, 41
- 10.1245/s10434-008-9876-3 · DOI
- 10.1002/jso.20642 · DOI · Paper page
- 10.1038/labinvest.3700055 · DOI · Paper page
- 10.1111/j.1365-2559.2007.02919.x · DOI
- 10.1111/j.1365-2559.2009.03379.x · DOI
- 10.1371/journal.pone.0018219 · DOI · Paper page
- 10.1200/JCO.2010.30.5037 · DOI · Paper page
- 10.1016/S0960-9776(03)00004-3 · doi:10.1016/s0960-9776(03)00004-3
- Matkowski R, 2009, The prognostic role of tumor‐infiltrating CD4 and CD8 T lymphocytes in breast cancer, Anticancer Res, 29, 2445
- 10.1093/annonc/mdl053 · DOI · Paper page
- 10.1002/jnr.10304 · DOI · Paper page
Cited by
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Monocyte heterogeneity and functions in cancer
Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0818-311r · Cited by 579
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
Patrolling monocytes control tumor metastasis to the lung
Hanna, R. N., Cekic, C., Sag, D., Tacke, R., Thomas, G. D., Nowyhed, H., Herrley, E., Rasquinha, N., McArdle, S., Wu, R., et al. (2015) · Science · doi:10.1126/science.aac9407 · Cited by 480
Metadata
- Authors
- Park, M. H., Lee, J. S., & Yoon, J. H.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2012-03-15
- Volume
- 106
- Issue
- 4
- Pages
- 386-392
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2120687087
- Cited by
- 121
- References
- 1
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Research Institute of Medical Sciences, Chonnam National University (2010-CURIMS-DR010)
- Ministry of Education, Science and Technology (2011-0030034)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.